Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34:927–935. doi:10.1200/JCO.2015.62.3504.
   PubMed Web of Science ®Google Scholar
• Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A. Cancer stem cells: the root of tumor recurrence and metastases. Semin Cancer Biol. 2017;44:10–24. doi:10.1016/j.semcancer.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;198:281–293. doi:10.1083/jcb.201202014.
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, De Giovanni C, Nanni P. Preclinical vaccines against mammary carcinoma. Expert Rev Vaccines. 2013;12:1449–1463. doi:10.1586/14760584.2013.845530.
   PubMed Web of Science ®Google Scholar
• Conti L, Ruiu R, Barutello G, Macagno M, Bandini S, Cavallo F, et al. Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. Biomed Res Int. 2014;2014:534969. doi:10.1155/2014/534969.
   PubMed Web of Science ®Google Scholar
• Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, et al. Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer. Cancer Res. 2016;76:62–72. doi:10.1158/0008-5472.CAN-15-1208.
   PubMed Web of Science ®Google Scholar
• De La Ballina LR, Cano-Crespo S, Gonzalez-Munoz E, Bial S, Estrach S, Cailleteau L, et al. Amino acid transport associated to cluster of differentiation 98 heavy chain (CD98hc) is at the cross-road of oxidative stress and amino acid availability. J Biol Chem. 2016;291:9700–9711. doi:10.1074/jbc.M115.704254.
   PubMed Web of Science ®Google Scholar
• Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids. 2012;42:231–246. doi:10.1007/s00726-011-0867-5.
   PubMed Web of Science ®Google Scholar
• Shin CS, Mishra P, Watrous JD, Carelli V, D’Aurelio M, Jain M, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074. doi:10.1038/ncomms15074.
   PubMed Web of Science ®Google Scholar
• Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450–465. doi:10.1016/j.ccr.2013.08.020.
   PubMed Web of Science ®Google Scholar
• Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215:593–602. doi:10.1002/jcp.21366.
   PubMed Web of Science ®Google Scholar
• Sugano K, Maeda K, Ohtani H, Nagahara H, Shibutani M, Hirakawa K. Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer. Anticancer Res. 2015;35:677–682.
   PubMed Web of Science ®Google Scholar
• Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, et al. Cell-surface marker discovery for lung cancer. Oncotarget. 2017;8:113373–113402. doi:10.18632/oncotarget.23009.
   PubMedGoogle Scholar
• Zhang L, Huang Y, Ling J, Zhuo W, Yu Z, Luo Y, et al. Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma. Future Oncol. 2018. doi:10.2217/fon-2017-0540.
   Web of Science ®Google Scholar
• Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013;32:5191–5198. doi:10.1038/onc.2012.638.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, et al. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016;7:11756–11769. doi:10.18632/oncotarget.7598.
   PubMed Web of Science ®Google Scholar
• Chen RS, Song YM, Zhou ZY, Tong T, Li Y, Fu M, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway. Oncogene. 2009;28:599–609. doi:10.1038/onc.2008.414.
   PubMed Web of Science ®Google Scholar
• Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-gamma-lyase function. Oncol Rep. 2015;33:1465–1474. doi:10.3892/or.2015.3712.
   PubMed Web of Science ®Google Scholar
• Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song M, et al. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Lett. 2015;368:88–96. doi:10.1016/j.canlet.2015.07.031.
   PubMed Web of Science ®Google Scholar
• Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119:1209–1218.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother. 2017;13:528–532. doi:10.1080/21645515.2016.1244149.
   PubMed Web of Science ®Google Scholar
• Wong KK, Li WA, Mooney DJ, Dranoff G. Advances in Therapeutic Cancer Vaccines. Adv Immunol. 2016;130:191–249. doi:10.1016/bs.ai.2015.12.001.
   PubMed Web of Science ®Google Scholar
• Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Cancer immunoprevention. Future Oncol. 2005;1:57–66. doi:10.1517/14796694.1.1.57.
   PubMedGoogle Scholar
• Bolli E, O’Rourke JP, Conti L, Lanzardo S, Rolih V, Christen JM, et al. A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo. OncoImmunology. 2017:e1408746. doi:10.1080/2162402X.2017.1408746.
   Google Scholar
• Jacca S, Rolih V, Quaglino E, Franceschi V, Tebaldi G, Bolli E, et al. Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancer. Oncoimmunology. 2016;5:e1082705. doi:10.1080/2162402X.2015.1082705.
   PubMed Web of Science ®Google Scholar
• Conti L, Lanzardo S, Arigoni M, Antonazzo R, Radaelli E, Cantarella D, et al. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J. 2013;27:4731–4744. doi:10.1096/fj.13-230201.
   PubMed Web of Science ®Google Scholar
• Capocefalo A, Franceschi V, Mertens PP, Castillo-Olivares J, Cavirani S, Di Lonardo E, et al. Expression and secretion of Bluetongue virus serotype 8 (BTV-8)VP2 outer capsid protein by mammalian cells. J Virol Methods. 2010;169:420–424. doi:10.1016/j.jviromet.2010.08.002.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Cavirani S, Simone T, Van Santen VL. Potential of bovine herpesvirus 4 as a gene delivery vector. J Virol Methods. 2002;101:49–61.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Sartori C, Franceschi V, Capocefalo A, Cavirani S, Taddei S, et al. Double immunization strategy with a BoHV-4-vectorialized secreted chimeric peptide BVDV-E2/BoHV-1-gD. Vaccine. 2008;26:6031–6042. doi:10.1016/j.vaccine.2008.09.023.
   PubMed Web of Science ®Google Scholar
• Franceschi V, Capocefalo A, Cavirani S, Donofrio G. Bovine herpesvirus 4 glycoprotein B is indispensable for lytic replication and irreplaceable by VSVg. BMC Vet Res. 2013;9:6. doi:10.1186/1746-6148-9-18.
   PubMed Web of Science ®Google Scholar
• Capocefalo A, Mangia C, Franceschi V, Jacca S, Van Santen VL, Donofrio G. Efficient heterologous antigen gene delivery and expression by a replication-attenuated BoHV-4-based vaccine vector. Vaccine. 2013;31:3906–3914. doi:10.1016/j.vaccine.2013.06.052.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Sartori C, Ravanetti L, Cavirani S, Gillet L, Vanderplasschen A, et al. Establishment of a bovine herpesvirus 4 based vector expressing a secreted form of the bovine viral diarrhoea virus structural glycoprotein E2 for immunization purposes. BMC Biotechnol. 2007;7:68. doi:10.1186/1472-6750-7-68.
   PubMed Web of Science ®Google Scholar
• Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, et al. Immunization of knock-out alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine. 2011;29:3074–3082. doi:10.1016/j.vaccine.2011.01.075.
   PubMed Web of Science ®Google Scholar
• Redaelli M, Franceschi V, Capocefalo A, D’Avella D, Denaro L, Cavirani S, et al. Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro Oncol. 2012;14:288–301. doi:10.1093/neuonc/nor219.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Franceschi V, Lovero A, Capocefalo A, Camero M, Losurdo M, et al. Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD. PLoS One. 2013;8:e52758. doi:10.1371/journal.pone.0052758.
   PubMed Web of Science ®Google Scholar
• Warming S, Costantino N, Dl C, Na J, Ng C. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 2005;33:e36. doi:10.1093/nar/gni035.
   PubMed Web of Science ®Google Scholar
• Franceschi V, Parker S, Jacca S, Crump RW, Doronin K, Hembrador E, et al. BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge. PLoS Negl Trop Dis. 2015;9:e0003850. doi:10.1371/journal.pntd.0003850.
   PubMed Web of Science ®Google Scholar
• Craig L, Sanschagrin PC, Rozek A, Lackie S, Kuhn LA, Scott JK. The role of structure in antibody cross-reactivity between peptides and folded proteins. J Mol Biol. 1998;281:183–201. doi:10.1006/jmbi.1998.1907.
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55. doi:10.1158/1078-0432.CCR-09-1630.
   PubMed Web of Science ®Google Scholar
• Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol. 2006;177:7626–7633.
   PubMed Web of Science ®Google Scholar
• Tallerico R, Conti L, Lanzardo S, Sottile R, Garofalo C, Wagner AK, et al. NK cells control breast cancer and related cancer stem cell hematological spread. Oncoimmunology. 2017;6:e1284718. doi:10.1080/2162402X.2017.1284718.
   PubMed Web of Science ®Google Scholar
• Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem. 1999;274:11455–11458.
   PubMed Web of Science ®Google Scholar
• Verna AE, Franceschi V, Tebaldi G, Macchi F, Menozzi V, Pastori C, et al. Induction of Antihuman C-C Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector. Front Immunol. 2017;8:1402. doi:10.3389/fimmu.2017.01402.
   PubMed Web of Science ®Google Scholar
• Fusella F, Secli L, Busso E, Krepelova A, Moiso E, Rocca S, et al. The IKK/NF-kappaB signaling pathway requires Morgana to drive breast cancer metastasis. Nat Commun. 2017;8:1636. doi:10.1038/s41467-017-01829-1.
   PubMed Web of Science ®Google Scholar
• Park IA, Hwang SH, Song IH, Heo SH, Kim YA, Bang WS, et al. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS One. 2017;12:e0182786. doi:10.1371/journal.pone.0182786.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4(+) T Cells, Their Differentiation and Function. Front Immunol. 2017;8:194. doi:10.3389/fimmu.2017.00194.
   PubMed Web of Science ®Google Scholar
• Ryoo IG, Lee SH, Kwak MK. Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance. Oxid Med Cell Longev. 2016;2016:2428153. doi:10.1155/2016/2428153.
   PubMedGoogle Scholar
• Fazzari J, Lin H, Murphy C, Ungard R, Singh G. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep. 2015;5:8380. doi:10.1038/srep08380.
   PubMed Web of Science ®Google Scholar
• Dornier E, Rabas N, Mitchell L, Novo D, Dhayade S, Marco S, et al. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat Commun. 2017;8:2255. doi:10.1038/s41467-017-02101-2.
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70:68–77. doi:10.1158/0008-5472.CAN-09-2587.
   PubMed Web of Science ®Google Scholar
• Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K-I, Moriguchi T, et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem. 2005;280:37423–37429. doi:10.1074/jbc.M506439200.
   PubMed Web of Science ®Google Scholar
• Ruiu R, Rolih V, Bolli E, Barutello G, Riccardo F, Quaglino E, et al. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. Cancer Immunol Immunother. 2018. doi:10.1007/s00262-018-2185-1.
   PubMed Web of Science ®Google Scholar
• Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A. 2015;112:E4600–9. doi:10.1073/pnas.1513433112.
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–7511. doi:10.1158/0008-5472.CAN-09-2994.
   PubMed Web of Science ®Google Scholar
• Geninatti Crich S, Cadenazzi M, Lanzardo S, Conti L, Ruiu R, Alberti D, et al. Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale. 2015;7:6527–6533. doi:10.1039/c5nr00352k.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Franceschi V, Capocefalo A, Taddei S, Sartori C, Bonomini S, et al. Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development. Clin Vaccine Immunol. 2009;16:1675–1686. doi:10.1128/CVI.00224-09.
   PubMed Web of Science ®Google Scholar
• Donofrio G, Cavaggioni A, Bondi M, Cavirani S, Flammini CF, Mucignat-Caretta C. Outcome of bovine herpesvirus 4 infection following direct viral injection in the lateral ventricle of the mouse brain. Microbes Infect. 2006;8:898–904. doi:10.1016/j.micinf.2005.10.016.
   PubMed Web of Science ®Google Scholar
• Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65:499–509. doi:10.1002/ana.21652.
   PubMed Web of Science ®Google Scholar
• Macagno M, Bandini S, Stramucci L, Quaglino E, Conti L, Balmas E, et al. Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice. J Immunol. 2014;192:5434–5441. doi:10.4049/jimmunol.1301248.
   PubMed Web of Science ®Google Scholar
• Bandini S, Macagno M, Hysi A, Lanzardo S, Conti L, Bello A, et al. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. Oncoimmunology. 2016;5:e1253653. doi:10.1080/2162402X.2016.1253653.
   PubMed Web of Science ®Google Scholar
• Conti L, De Palma R, Rolla S, Boselli D, Rodolico G, Kaur S, et al. Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-gammaR2. J Immunol. 2012;188:1011–1018. doi:10.4049/jimmunol.1004013.
   PubMed Web of Science ®Google Scholar
• Conti L, Lanzardo S, Ruiu R, Cadenazzi M, Cavallo F, Aime S, et al. L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. Oncotarget. 2016;7:66713–66727. doi:10.18632/oncotarget.10920.
   PubMed Web of Science ®Google Scholar